News Release

Norfolk, VA, October 12, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company focused on harnessing the power of the immune system to address life-threatening diseases, was pleased to welcome Senator Mark R. Warner (D-Va) for an in-depth visit with the ReAlta management team, members of the ReAlta board of directors, and local investors on October 2, 2023.

During his visit, Senator Warner participated in an active discussion with members of ReAlta’s management team about the company’s ongoing clinical trials and development plans for commercial applications for its EPICC drug platform that will benefit patients suffering from acute inflammatory diseases such as hypoxic-ischemic encephalopathy (HIE), graft-versus-host disease (GvHD) and acute pulmonary exacerbations. The Senator, who is chairman of the Senate Select Committee on Intelligence, also learned about other research initiatives ReAlta is pursuing to treat life-threatening inflammatory conditions such as Acute Respiratory Distress Syndrome (ARDS) triggered by a pandemic virus, Acute Radiation Syndrome, and Sepsis that are of interest to the Department of Defense, BARDA, and other Federal agencies.

“We were honored to host Senator Warner and appreciated his interest in our efforts to treat patients with HIE and GvHD, as well as patients suffering from a number of pulmonary diseases,” said Ulrich Thienel, MD, PhD, CEO of ReAlta Life Sciences. “With the potential applications for our EPICC platform to treat medical threats faced by our military personnel on the battlefield and our civilian population after another pandemic virus, this visit by Senator Warner underlines the important role that companies like ReAlta can play in our national economy and healthcare infrastructure.”

“ReAlta is on the cutting edge of research in a variety of fronts – from COVID to birth asphyxia,” said Sen. Mark R. Warner. “I’m proud that Virginia is home to such an energetic and nimble company, and I look forward to seeing their work continue to push the boundaries in treating acute inflammatory and rare diseases.”

ReAlta is grateful to Senator Warner for his visit and his ongoing support for biotechnology innovation in Virginia. The company looks forward to continuing to push the boundaries of what is possible in the fight against life-threatening rare diseases.

About ReAlta Life Sciences

ReAlta Life Sciences, Inc. is a clinical mid-stage biotech company dedicated to harnessing the power of the immune system to address life threatening acute inflammatory and rare diseases. The Company’s EPICC peptides are based on research into the human astrovirus, HAstV-1, which causes a non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system. ReAlta’s therapeutic peptides leverage these virus-derived mechanisms to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071, which has received IND clearance by the U.S. Food and Drug Administration (FDA) for the treatment of acute Graft-versus-Host Disease and IND clearance, Orphan Drug Designation, and Fast Track Designation by the FDA, and Orphan Drug Designation by the European Medicines Agency, for the treatment of hypoxic-ischemic encephalopathy (HIE). The company launched in 2018 and is located in Norfolk, Virginia. For more information, please visit www.realtalifesciences.com.

Media and Investor Contact:
John Rickman
Chief Financial Officer
jrickman@realtals.com